EYPT
EyePoint Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2005-01-27
$4.51
-0.28 (-5.74%)
last quote
Want the full multi-source brief on EYPT?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$4.51
High
$4.92
Low
$4.50
Previous close
$4.79
Fundamentals
Market cap
$1.15B
P/E (TTM)
—
P/S (TTM)
412.98x
P/B
4.94x
Gross margin
41.77%
Operating margin
-11365.22%
Net margin
-10994.73%
Rev growth (YoY)
-94.63%
EPS growth (YoY)
—
ROE
-135.81%
52W high
$19.11
52W low
$3.95
Beta
1.58x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-03in 60 days
Q3 2026EPS est $-0.92Rev est $0.2M
Recent SEC filings
CIK 1314102filing-language history →
Recent news
2026-08-27 → 2026-09-03
Benzinga · 1d
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
Benzinga · 1d
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4
TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the price target from $20 to $4.
SeekingAlpha · 7d
EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
Apellis and Lytenava, mentioned by EyePoint, confirm that it is possible to overcome the failure of one pivotal trial. See why I rate EYPT stock a strong buy.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial